Assad Shawn
Known title: Chief Accounting OfficerCIK: 0001873887
Associated companies
Transaction History
| WGS | ▼ Sell | Open Market | 3,166 | $7K | 8/12/2022 | View on chart |
| WGS | ▲ Buy | Option Exercise | 10,457 | — | 8/10/2022 | View on chart |
| WGS | ▼ Sell | Open Market | 1,497 | $2K | 7/5/2022 | View on chart |
| WGS | ▲ Buy | Option Exercise | 5,139 | — | 7/1/2022 | View on chart |
| WGS | ▼ Sell | Open Market | 3,128 | $5K | 5/11/2022 | View on chart |
| WGS | ▲ Buy | Option Exercise | 10,457 | — | 5/10/2022 | View on chart |
| WGS | ▼ Sell | Open Market | 3,647 | $13K | 2/11/2022 | View on chart |
| WGS | ▲ Buy | Option Exercise | 10,457 | — | 2/10/2022 | View on chart |
| WGS | ▼ Sell | Tax Withholding | 82 | $453 | 12/1/2021 | View on chart |
| WGS | ▲ Buy | Grant | 249 | $2K | 12/1/2021 | View on chart |
| WGS | ▲ Buy | Option Exercise | 10,457 | — | 11/10/2021 | View on chart |
| WGS | ▼ Sell | Open Market | 3,114 | $25K | 11/10/2021 | View on chart |
| WGS | ▲ Buy | Option Exercise | 10,457 | — | 10/25/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
GeneDx Shares New Genomic Newborn Screening Data
GeneDx presented new evidence for its genomic newborn screening program at the ICoNS 2026 conference. This update highlights the company's ongoing development in clinical genomics. The stock is currently trading near its 52-week low, with an average analyst target of $93.50.
GeneDx Shares New Genomic Newborn Screening Data. GeneDx presented new evidence for its genomic newborn screening program at the ICoNS 2026 conference. This update highlights the company's ongoing development in clinical genomics. The stock is currently trading near its 52-week low, with an average analyst target of $93.50.